Context Therapeutics Inc. (CNTX)
(Real Time Quote from BATS)
$2.17 USD
+0.05 (2.36%)
Updated Jul 22, 2024 11:58 AM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
CNTX 2.17 +0.05(2.36%)
Will CNTX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CNTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CNTX
Is CareCloud (CCLD) Stock Outpacing Its Medical Peers This Year?
Are You Looking for a Top Momentum Pick? Why Context Therapeutics Inc. (CNTX) is a Great Choice
CNTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Context Therapeutics Inc. (CNTX) Upgraded to Buy: Here's Why
Nasdaq ETF's First Six-week Rally Since Jan 2020: Stock Winners
Other News for CNTX
Context Therapeutics Acquires Phase 1-ready T cell Engager CT-95
Hypergrowth Hits: 3 Stocks Clocking Triple-Digit Gains with No End in SightÂ
Context Therapeutics files to sell 64.52M shares of common stock for holders
The 100%+ Club: Piper Sandler’s 3 Top Picks for Triple-Digit Gains
Context Therapeutics initiated with bullish view at Piper Sandler, here's why